Interleukin-1β converting enzyme subfamily inhibitors prevent induction of CD86 molecules by butyrate through a CREB-dependent mechanism in HL60 cells

Immunology

Volumn 108, Issue 3, 2003, Pages 375-383

  Suzuki, M ^a   Shinohara, F ^a   Sato, K ^a   Taniguchi, T ^a   Takada, H ^a   Rikiishi, H ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BUCLADESINE; BUTYRIC ACID; CASPASE 5; CASPASE INHIBITOR; CD86 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; PYRROLIDINE DITHIOCARBAMATE; BUTYRIC ACID DERIVATIVE; CASPASE; CD86 PROTEIN, HUMAN; ENZYME INHIBITOR; HISTONE DEACETYLASE; INTERLEUKIN-1BETA-CONVERTING ENZYME INHIBITOR; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MESSENGER RNA; RNA; SERINE PROTEINASE INHIBITOR; TUMOR ANTIGEN; VIRUS PROTEIN;

ACETYLATION; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL STRAIN HL 60; CYCLIC AMP RESPONSIVE ELEMENT; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DNA BINDING; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM;

ANTIGENS, CD; ANTIGENS, CD86; ANTIGENS, NEOPLASM; APOPTOSIS; BUTYRATES; CASPASES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HL-60 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; RNA, MESSENGER; RNA, NEOPLASM; SERPINS; TRANSCRIPTION, GENETIC; VIRAL PROTEINS;

EID: 0037342560     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2003.01597.x     Document Type: Article

References (43)

1. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993; 14:483-6.
2. Krummel MF. Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995; 182:459-65.
3. Hirano N, Takahashi T, Ohtake S et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996; 10:1168-76.
4. Costello RT. Mallet F. Sainty D, Maraninchi D, Gastaut JA, Olive D. Regulation of CD80/B7-1 and CD86/BT-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition. Eur J Immunol 1998; 28:90-103.
5. Koski GK, Schwartz GN, Weng DE, Gress RE, Engels FHC, Tsokos M, Czerniecki BJ, Cohen PA. Calcium ionophore-treated myeloid cells acquire many dendritic cell characteristics independent of prior differentiation state, transformation status, or sensitivity to biologic agents. Blood 1999; 94:1359-71.
6. Maeda T, Towatari M, Kosugi H, Saito H. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood 2000; 96:3847-56.
7. Yang G, Hellström KE, Hellström I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995; 154:2794-800.
8. Heerdt BG. Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 1994; 54:3288-93.
9. Janson W, Brandner G, Siegel J. Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene 1997; 15:1395-406.
10. Heruth DP. Zirnstein GW. Bradley JF, Rothberg PG. Sodium butyrate causes an increase in the block to transcriptional elongation in the c-myc gene in SW837 rectal carcinoma cells. J Biol Chem 1993; 268:20466-72.
11. Nakano K, Mizuno T, Sowa Y el al. Butyrate activates the WAF1/ Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 1997; 272:22199-206.
12. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982; 42:65-82.
13. Zhao J, Freeman GJ, Gray GS, Nadler LM, Glimcher LH. A cell type-specific enhancer in the human B7.1 gene regulated by NF-κB. J Exp Med 1996; 183:777-89.
14. Li J, Liu Z, Jiang S, Cortesini R. Ledermann S, Suciu-Foca N T suppressor lymphocytes inhibit NF-κB-mediated transcription of CD86 gene in APC. J Immunol 1999; 163:6386-92.
15. Van de Stolpe A, Caldenhoven E, Stade BG, Koenderman L, Raaijmakers JAM, Johnson JP, van der Saag PT. 12-O-tetradecanoylphorbol-13-acetate-and tumor necrosis factor α-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994; 269:6185-92.
16. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90:1621-5.
17. Takahashi M, Takahashi M, Shinohara F, Takada H, Rikiishi H. Effects of superantigen and lipopolysaccharide on induction of CD80 through apoptosis of human monocytes. Infect Immun 2001; 69:3652-7.
18. Pahl HL. Activators and target genes of Re1/NF-κB transcription factors. Oncogene 1999; 18:6853-66.
19. Lalli E, Sassone-Corsi P. Signal transduction and gene regulation: the nuclear response to cAMP. J Biol Chem 1994; 269:17359-62.
20. Ziegler-Heitbrock HW, Sternsdorf T, Liese J et al. Pyrrolidine dithiocarbamate inhibits NF-κB mobilization and TNF production in human monocytes. J Immunol 1993; 151:6986-93.
21. Jellis CL, Wang SS, Rennert P, Borriello F, Sharpe AH, Green NR, Gray GS. Genomic organization of the gene coding for the costimulatory human B-lymphocyte antigen B7-2 (CD86). Immunogenetics 1995; 42:85-9.
22. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993; 178:669-74.
23. Francis DA, Karras JG, Ke XY, Sen R. Rothstein TL. Induction of the transcription factors NF-κB, AP-1 and NF-AT during B cell stimulation through the CD40 receptor. Int Immunol 1995; 7:151-61.
24. Karras JG, Wang Z, Huo L, Frank DA, Rothstein TL. Induction of STAT protein signaling through the CD40 receptor in B lymphocytes: distinct STAT activation following surface Ig and CD40 receptor engagement. J Immunol 1997; 159:4350-5.
25. Bhushan A, Covey LR. CREB/ATF proteins enhance the basal and CD154-and IL-4-induced transcriptional activity of the human Iγ1 proximal promoter. Eur J Immunol 2001; 31:653-64.
26. Berberich I, Shu GL, Clark EA. Cross-linking CD40 on B cells rapidly activates nuclear factor-κB. J Immunol 1994; 153:4357-66.
27. Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998; 1:661-71.
28. Witt O, Sand K, Pekrun A. Butyrate-induced erythroid differentiation of human K562 leukemia cells involves inhibition of ERK and activation of p38 MAP kinase pathways. Blood 2000; 95:2391-6.
29. Carter AB, Knudtson KL, Monick MM, Hunninghake GW. The p38 mitogen-activated protein kinase is require, d for NF-κB-dependent gene expression. J Biol Chem 1999; 274:30858-63.
30. Xing J, Ginty DD, Greenberg ME. Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996; 273:959-63.
31. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P. Gallagher TF, Young PR, Lee JC. SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995; 364:229-33.
32. Dudley DT, Pang L. Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 1995; 92:7686-9.
33. Cuisset L, Tichonicky L. Delpech M. A protein phosphatase is involved in the inhibition of histone deacetylation by sodium butyrate. Biochem Biophys Res Commun 1998; 246:760-4.
34. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993; 72:73-84.
35. Berger SL. Gene activation by histone and factor acetyltransferases. Curr Opin Cell Biol 1999; 11:336-41.
36. Bannister AJ, Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996; 384:641-3.
37. Sheppard KA, Rose DW, Haque ZK et al. Transcriptional activation by NF-κB requires multiple coactivators. Mol Cell Biol 1999; 19:6367-78.
38. Korzus E, Torchia J, Rose DW et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998; 279:703-7.
39. Medina V. Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997; 57:3697-707.
40. Giuliano M, Lauricella M, Calvaruso G, Carabillo M, Emanuele S, Vento R. Tesoriere G. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 1999; 59:5586-95.
41. Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16:5546-56.
42. Avivi-Green C, Polak-Charcon S, Madar Z, Schwartz B. Apoptosis cascade proteins are regulated in vivo by high intracolonic butyrate concentration: correlation with colon cancer inhibition. Oncol Res 2000; 12:83-95.
43. Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem 1999; 274:20049-52.